Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the BIO International Convention 2026 Partnering Event, held June 22–25, 2026 in San Diego. Management plans partnering meetings focused on Phase 3‑ready CAD-1005 for Heparin-Induced Thrombocytopenia (HIT), its broader 12-LOX inhibitor platform, and late-stage oral anticoagulant tecarfarin.
CAD-1005 has completed an End-of-Phase 2 FDA meeting outlining a single pivotal Phase 3 path, following Phase 2 data suggesting reduced thrombotic events in HIT. The 12-LOX platform targets inflammatory and metabolic diseases, while tecarfarin holds FDA Orphan Drug and Fast Track designations for high-risk ESRD/AFib and LVAD-related populations.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CVKD
-3.68%
4 alerts
-3.68%Session close to close
+4.5%Peak Tracked
$12.92MMarket Cap
0.1xRel. Volume
In the Jun 3 session, CVKD declined 3.68%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +4.5% during that session.
Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights a Phase 3‑ready CAD-1005 program in HIT, broader 12‑LOX platform ambiti...
Analysis
This announcement highlights a Phase 3‑ready CAD-1005 program in HIT, broader 12‑LOX platform ambitions, and late‑stage tecarfarin positioned for complex anticoagulation settings. Historically, clinical milestones for these assets have driven meaningful moves, with same‑tag news averaging 12.58%. Investors may watch for concrete Phase 3 initiation, partnering outcomes from BIO 2026, updates on tecarfarin trial execution, and how the existing S-3 resale shelf and recent insider sales intersect with ongoing funding needs.
Key Figures
Peak annual revenue potential:$2 billion
1 metrics
Peak annual revenue potential$2 billionTarget for CAD-1005 in prevention of HIT-related blood clots
New Chief Medical Officer appointed to lead late-stage tecarfarin development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Clinical trial updates have typically produced positive moves, with same-tag events averaging a 12.58% price reaction.
Recent Company History
Over the past year, Cadrenal has steadily advanced its clinical pipeline. For CAD-1005 in HIT, the company reported Phase 2 data with >25% absolute thrombotic reduction and then secured FDA End-of-Phase 2 guidance for a pivotal Phase 3 trial, driving reactions of 16.1% and 19.32%. Tecarfarin has progressed through manufacturing milestones and trial initiation planning in high‑risk cardiovascular settings. Today’s BIO 2026 partnering focus fits this pattern of showcasing late-stage assets and platform potential.
Key Terms
heparin-induced thrombocytopenia, 12-lipoxygenase, 12-lox, orphan drug, +4 more
8 terms
heparin-induced thrombocytopeniamedical
"being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT)"
An immune reaction to the blood-thinning drug heparin that destroys or disables platelets, the blood cells that stop bleeding, while paradoxically increasing the risk of dangerous clots. Think of it as the body’s security system misidentifying helpful staff and triggering chaos that both lowers protection and creates blockages. Investors care because it can change demand for drugs and devices, drive safety warnings or lawsuits, and affect hospital treatment costs and clinical trial outcomes.
12-lipoxygenasemedical
"a Phase 3-ready 12-lipoxygenase (12-LOX) inhibitor being investigated for the treatment"
12-lipoxygenase is an enzyme that acts like a factory machine inside cells, turning certain fatty molecules into signaling chemicals that affect inflammation, blood clotting and cell growth. Investors care because changes in its activity are linked to diseases such as cardiovascular disease, cancer and diabetic complications, so it is a potential drug target, biomarker or diagnostic focus that can drive the value of therapies and related companies.
12-loxmedical
"12-LOX could play a central role in inflammatory signaling across high-impact disease areas"
12-lox is an enzyme that acts like a cellular factory, turning a common fat molecule into signaling chemicals that influence inflammation, blood clotting, and cell growth. Investors watch it because drugs or tests that block or measure 12-lox activity can change outcomes for diseases such as heart disease, diabetes complications, and certain cancers, creating potential markets for therapies, diagnostics, or companion treatments.
orphan drugregulatory
"Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
fast trackregulatory
"has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
vitamin k antagonistmedical
"tecarfarin, a late-stage oral Vitamin K antagonist (VKA) for being investigated"
A vitamin K antagonist is a type of medication that reduces the blood’s ability to form clots by blocking vitamin K, which the body needs to make clotting proteins; think of it as dimming the switch that helps blood solidify. It matters to investors because these drugs are central to markets for stroke and thrombosis prevention, carry safety and monitoring requirements that affect use and costs, and are sensitive to clinical trial results, regulation and patent changes.
left ventricular assist devicesmedical
"support devices, including Left Ventricular Assist Devices (LVADs)"
Left ventricular assist devices are implantable mechanical pumps that help a failing left side of the heart move blood through the body, acting like an auxiliary motor for the heart. They matter to investors because demand, device performance, regulatory approval, and reimbursement rules drive sales, long-term service revenue, and clinical adoption, all of which affect the financial prospects of medical device makers, hospitals, and healthcare payers.
atrial fibrillationmedical
"End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with"
Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential
12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer
Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs)
PONTE VEDRA, Fla., June 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced its participation in the BIO International Convention 2026 Partnering Event (BIO 2026) taking place June 22–25, 2026, at the San Diego Convention Center.
The Company’s executive management team will host partnering meetings to discuss development and commercialization opportunities for its differentiated pipeline, headlined by CAD-1005, a Phase 3-ready 12-lipoxygenase (12-LOX) inhibitor being investigated for the treatment of patients with Heparin-Induced Thrombocytopenia (HIT), and tecarfarin, a late-stage oral Vitamin K antagonist (VKA) for being investigated for the treatment of patients with conditions for which current anticoagulation profiles are ineffective or suboptimal.
"BIO 2026 comes at a pivotal moment for Cadrenal as we prepare to initiate our Phase 3 registration trial for CAD-1005," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. "With Orphan Drug and Fast Track designations from the FDA, we believe we are uniquely positioned to address the significant unmet need in HIT, a condition where no new therapies have been approved in over two decades. We look forward to engaging with potential partners who share our vision of the potential to bring this breakthrough mechanism to patients."
Highlighting CAD-1005: A Potential First-in-Class Solution for HIT At the forefront of Cadrenal’s portfolio is CAD-1005, the only selective 12-LOX inhibitor known to us to be currently in clinical development. CAD-1005 is being investigated to target the root cause of HIT—a severe, immune-mediated reaction to heparin that causes life-threatening blood clots and low platelet counts. Unlike current therapies that only reduce the risk of thrombotic complications, CAD-1005 is being investigated to interrupt the immune signaling feedback loop that drives the development and persistence of HIT.
The Company recently completed an End-of-Phase 2 (EOP2) meeting with the FDA, which provided guidance on the registration path for a single pivotal Phase 3 trial. This follows Phase 2 data demonstrating that CAD-1005 could reduce thrombotic events in patients with HIT.
Unlocking the Potential of the 12-LOX Platform Beyond HIT, Cadrenal is leveraging the BIO 2026 partnering forum to explore broader applications for its proprietary 12-LOX inhibitor platform. Emerging research indicates that 12-LOX may play a central role in inflammatory signaling across high-impact disease areas, including atherosclerosis, microvascular thrombosis, and metabolic conditions such as diabetes and obesity. Additionally, 12-LOX is a potential target for therapy and prevention of cancer.
The Company’s platform represents a novel approach to modulating inflammation without the broader systemic suppression associated with traditional anti-inflammatory agents. Cadrenal aims to identify strategic collaborations to accelerate the development of its second-generation oral 12-LOX inhibitors (CAD-2000) for these chronic, large-market indications.
Tecarfarin: A Potentially Superior Anticoagulant for Complex Cases Cadrenal will also present opportunities for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is being designed with the goal of being uniquely metabolized in ways that avoid the drug-drug interactions and renal clearance issues common with warfarin and direct oral anticoagulants (DOACs). Tecarfarin has already received FDA Orphan Drug and Fast Track designations for two specific high-risk populations - patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).
About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is being researched as a first-in-class 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements regarding the Company showcasing its Phase 3-ready CAD-1005 and novel 12-LOX platform at BIO 2026; CAD-1005 being researched for the prevention of life-threatening blood clots in patients with HIT; CAD-1005 targeting $2 billion peak annual revenue potential; 12-LOX playing a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis; 12-LOX being a potential target for therapy and prevention of cancer; the Company advancing novel therapies for life-threatening immune and thrombotic conditions; the Company’s participation in BIO 2026, taking place June 22–25, 2026, at the San Diego Convention Center; the Company’s executive management team hosting partnering meetings to discuss development and commercialization opportunities for its differentiated pipeline, headlined by CAD-1005, a Phase 3-ready 12-LOX inhibitor being investigated for the treatment of patients with HIT, and tecarfarin, a late-stage oral VKA being investigated for the treatment of patients with conditions for which current anticoagulation profiles are ineffective or suboptimal; Cadrenal preparing to initiate its Phase 3 registration trial for CAD-1005; the Company believing it is uniquely positioned to address the significant unmet need in HIT, a condition where no new therapies have been approved in over two decades; the Company engaging with potential partners who share its vision of the potential to bring this breakthrough mechanism to patients; CAD-1005 being a potential first-in-class solution for HIT; CAD-1005 being investigated to target the root cause of HIT; CAD-1005 being investigated to interrupt the immune signaling feedback loop that drives the development and persistence of HIT; CAD-1005 reducing thrombotic events in patients with HIT; Cadrenal leveraging the BIO 2026 partnering forum to explore broader applications for its proprietary 12-LOX inhibitor platform; 12-LOX playing a central role in inflammatory signaling across high-impact disease areas, including atherosclerosis, microvascular thrombosis, and metabolic conditions such as diabetes and obesity; 12-LOX being a potential target for therapy and prevention of cancer; the Company’s platform representing a novel approach to modulating inflammation without the broader systemic suppression associated with traditional anti-inflammatory agents; Cadrenal aiming to identify strategic collaborations to accelerate the development of its second-generation oral 12-LOX inhibitors (CAD-2000) for these chronic, large-market indications; tecarfarin being a potentially superior anticoagulant for complex cases; Cadrenal presenting opportunities for tecarfarin, its late-stage oral anticoagulant, at BIO 2026; tecarfarin being designed with the goal of being a uniquely metabolized in ways that avoid the drug-drug interactions and renal clearance issues common with warfarin and DOACs; Cadrenal advancing novel therapies for life-threatening immune and thrombotic conditions; CAD-1005 being researched as a first-in-class 12-LOX inhibitor for treating HIT; the development of second-generation 12-LOX oral therapeutics for chronic indications; tecarfarin preventing heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices; and frunexian being used in acute hospital settings. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to raise sufficient capital to continue progress of CAD-1005; the ability to advance directly to Phase 3 study evaluating CAD-1005 in patients with HIT; the ability to successfully design and complete the Phase 3 study and derive the results needed for an NDA submission; and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
What will Cadrenal Therapeutics (Nasdaq: CVKD) present at BIO International Convention 2026?
Cadrenal Therapeutics will present partnering opportunities around CAD-1005, its 12-LOX platform, and tecarfarin. According to Cadrenal Therapeutics, executives will use BIO 2026 meetings to discuss development and commercialization paths for HIT, inflammatory and metabolic diseases, and complex anticoagulation cases.
What is CAD-1005 and how is Cadrenal Therapeutics developing it for HIT (CVKD)?
CAD-1005 is a Phase 3-ready, selective 12-LOX inhibitor being investigated for Heparin-Induced Thrombocytopenia (HIT). According to Cadrenal Therapeutics, Phase 2 data suggested reduced thrombotic events, and an FDA End-of-Phase 2 meeting outlined a registration path via a single pivotal Phase 3 trial.
What market opportunity does CAD-1005 target for Cadrenal Therapeutics (CVKD) in HIT?
CAD-1005 targets a potential $2 billion peak annual revenue opportunity in HIT, according to Cadrenal Therapeutics. The company is investigating CAD-1005 to address immune-mediated blood clots in patients with heparin-induced thrombocytopenia, where no new therapies have been approved in over two decades.
What is Cadrenal Therapeutics’ 12-LOX inhibitor platform and which diseases could it impact?
Cadrenal’s 12-LOX platform targets inflammatory signaling implicated in several serious diseases. According to Cadrenal Therapeutics, potential applications include atherosclerosis, microvascular thrombosis, diabetes, obesity, and cancer prevention or therapy, with second-generation oral 12-LOX inhibitors (CAD-2000) being advanced for chronic, large-market indications.
What is tecarfarin and which patient groups have FDA designations, according to Cadrenal Therapeutics (CVKD)?
Tecarfarin is a late-stage oral vitamin K antagonist anticoagulant designed to limit drug interactions and renal issues. According to Cadrenal Therapeutics, tecarfarin has FDA Orphan Drug and Fast Track designations for patients with ESRD and atrial fibrillation, and those with mechanical circulatory support devices including LVADs.
When and where is BIO International Convention 2026, and how is Cadrenal Therapeutics involved?
BIO International Convention 2026 runs June 22–25, 2026, at the San Diego Convention Center. According to Cadrenal Therapeutics, the company’s executive team will attend the partnering event, holding meetings to explore collaborations around CAD-1005, the 12-LOX platform, and tecarfarin.
